| Total (n = 192) | Transfer (n = 38) | Non-Transfer (n = 154) | p value |
Demographic Data | ||||
Age (median, IQR) | 80 [66 - 86] | 67 [60.5 - 80.75] | 81 [68 - 87] | 0.0008 |
Gender (Men/Women) % | 96/96 | 22/16 | 74/80 | 0.3651 |
Functional Status and Medical History | ||||
Barthel Index (median, IQR) | 100 [78.75 - 100] | 100 [96.25 - 100] | 100 [66.25 - 100] | 0.0193 |
Barthel Index < 60 | 30 | 1 | 29 | 0.0268 |
mRankin (median, IQR) | 0 [0 - 2] | 0 [0 - 1] | 0 [0 - 3] | 0.0284 |
mRankin ≤ 1 | 135 | 32 | 103 | 0.0465 |
Charlson Index (mean, SD) | 4.45 (2.14) | 3.89 | 4.58 | 0.0791 |
Smoke | 33 | 9 | 24 | 0.3809 |
Hypertension | 126 | 22 | 104 | 0.3526 |
Diabetes mellitus | 47 | 10 | 37 | 0.9336 |
Dyslipidemia | 74 | 16 | 58 | 0.7506 |
Cognitive impairment | 40 | 4 | 36 | 0.1275 |
Atrial fibrillation | 42 | 9 | 33 | 0.9345 |
Mitral valvulopathy | 22 | 3 | 19 | 0.5764 |
Peripheral arteriopathy | 13 | 0 | 13 | 0.0752 |
Ischemic cardiopathy | 18 | 3 | 15 | 0.9999 |
acetylsalicylic acid 100 mg | 53 | 9 | 44 | 0.6884 |
acetylsalicylic acid 300 mg | 9 | 1 | 8 | 0.6911 |
P2Y12 inhibitors | 14 | 1 | 13 | 0.3096 |
Vitamin K inhibitors | 22 | 5 | 17 | 0.7763 |
Direct oral anticoagulants | 7 | 3 | 4 | 0.1408 |
Angiotensin II converting enzyme inhibitors | 47 | 6 | 41 | 0.2378 |
Angiotensin II receptor antagonists | 19 | 5 | 14 | 0.5426 |
Lipid-lowering drugs | 60 | 13 | 47 | 0.8070 |